JP2012148089A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012148089A5 JP2012148089A5 JP2012045526A JP2012045526A JP2012148089A5 JP 2012148089 A5 JP2012148089 A5 JP 2012148089A5 JP 2012045526 A JP2012045526 A JP 2012045526A JP 2012045526 A JP2012045526 A JP 2012045526A JP 2012148089 A5 JP2012148089 A5 JP 2012148089A5
- Authority
- JP
- Japan
- Prior art keywords
- organic material
- beneficial organic
- beneficial
- porous semiconductor
- impregnation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000009286 beneficial effect Effects 0.000 claims 46
- 239000011368 organic material Substances 0.000 claims 37
- 239000004065 semiconductor Substances 0.000 claims 28
- 238000000034 method Methods 0.000 claims 23
- 238000005470 impregnation Methods 0.000 claims 17
- 239000000463 material Substances 0.000 claims 17
- 238000002844 melting Methods 0.000 claims 9
- 230000008018 melting Effects 0.000 claims 9
- 239000000126 substance Substances 0.000 claims 9
- 229910052710 silicon Inorganic materials 0.000 claims 6
- 239000010703 silicon Substances 0.000 claims 6
- 239000002131 composite material Substances 0.000 claims 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims 4
- 238000010438 heat treatment Methods 0.000 claims 4
- VCMMXZQDRFWYSE-UHFFFAOYSA-N plumbagin Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1O VCMMXZQDRFWYSE-UHFFFAOYSA-N 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 239000011148 porous material Substances 0.000 claims 3
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 2
- ZMOIGGHUSNHCAB-UHFFFAOYSA-N Isoplumbagin Natural products C1=CC(O)=C2C(=O)C(C)=CC(=O)C2=C1 ZMOIGGHUSNHCAB-UHFFFAOYSA-N 0.000 claims 2
- 239000005639 Lauric acid Substances 0.000 claims 2
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 229930003427 Vitamin E Natural products 0.000 claims 2
- 229930003448 Vitamin K Natural products 0.000 claims 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims 2
- 229960000836 amitriptyline Drugs 0.000 claims 2
- 239000003125 aqueous solvent Substances 0.000 claims 2
- ALPCEXCHMFUSAN-UHFFFAOYSA-N beta-Dihydroplumbagin Natural products C1=CC=C2C(=O)C(C)CC(=O)C2=C1O ALPCEXCHMFUSAN-UHFFFAOYSA-N 0.000 claims 2
- 229960002092 busulfan Drugs 0.000 claims 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical group OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 2
- 229960004630 chlorambucil Drugs 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229960003957 dexamethasone Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 2
- 229960001680 ibuprofen Drugs 0.000 claims 2
- 229940033355 lauric acid Drugs 0.000 claims 2
- 229960001614 levamisole Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims 2
- 229960002985 medroxyprogesterone acetate Drugs 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims 2
- 229910021426 porous silicon Inorganic materials 0.000 claims 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims 2
- 229960004919 procaine Drugs 0.000 claims 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims 2
- 229960001225 rifampicin Drugs 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 235000019165 vitamin E Nutrition 0.000 claims 2
- 229940046009 vitamin E Drugs 0.000 claims 2
- 239000011709 vitamin E Substances 0.000 claims 2
- 235000019168 vitamin K Nutrition 0.000 claims 2
- 239000011712 vitamin K Substances 0.000 claims 2
- 150000003721 vitamin K derivatives Chemical class 0.000 claims 2
- 229940046010 vitamin k Drugs 0.000 claims 2
- 229910052581 Si3N4 Inorganic materials 0.000 claims 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims 1
- 238000009835 boiling Methods 0.000 claims 1
- 229910052732 germanium Inorganic materials 0.000 claims 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 claims 1
- 229910010271 silicon carbide Inorganic materials 0.000 claims 1
- HQVNEWCFYHHQES-UHFFFAOYSA-N silicon nitride Chemical compound N12[Si]34N5[Si]62N3[Si]51N64 HQVNEWCFYHHQES-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0324482.9 | 2003-10-21 | ||
| GB0324482A GB0324482D0 (en) | 2003-10-21 | 2003-10-21 | Methods for the treatment of cancer |
| GB0324483.7 | 2003-10-21 | ||
| GBGB0324483.7A GB0324483D0 (en) | 2003-10-21 | 2003-10-21 | Composite material |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006536166A Division JP2007533643A (ja) | 2003-10-21 | 2004-10-21 | 有機物質が含浸された多孔性半導体を含む複合材料 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012148089A JP2012148089A (ja) | 2012-08-09 |
| JP2012148089A5 true JP2012148089A5 (enExample) | 2013-05-30 |
Family
ID=34553784
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006536166A Pending JP2007533643A (ja) | 2003-10-21 | 2004-10-21 | 有機物質が含浸された多孔性半導体を含む複合材料 |
| JP2012045526A Withdrawn JP2012148089A (ja) | 2003-10-21 | 2012-03-01 | 有機物質が含浸された多孔性半導体を含む複合材料 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006536166A Pending JP2007533643A (ja) | 2003-10-21 | 2004-10-21 | 有機物質が含浸された多孔性半導体を含む複合材料 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070042046A1 (enExample) |
| EP (2) | EP1677828B1 (enExample) |
| JP (2) | JP2007533643A (enExample) |
| DK (1) | DK1677828T3 (enExample) |
| ES (1) | ES2401435T3 (enExample) |
| SI (1) | SI1677828T1 (enExample) |
| WO (2) | WO2005041936A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9808052D0 (en) | 1998-04-17 | 1998-06-17 | Secr Defence | Implants for administering substances and methods of producing implants |
| GB0526332D0 (en) * | 2005-12-23 | 2006-02-01 | Psimedica Ltd | Pharmaceutical product |
| US20070258903A1 (en) * | 2006-05-02 | 2007-11-08 | Kleiner Lothar W | Methods, compositions and devices for treating lesioned sites using bioabsorbable carriers |
| DE102006028783B4 (de) * | 2006-06-23 | 2014-09-18 | Robert Bosch Gmbh | Poröser Siliziumkörper mit schichtartigem Aufbau, Verfahren zu dessen Herstellung sowie Verwendung desselben |
| FR2937249B1 (fr) * | 2008-10-17 | 2012-12-21 | Centre Nat Rech Scient | Nouvelles utilisations pharmaceutiques de nanoparticules. |
| AU2010246067B2 (en) * | 2009-05-04 | 2016-07-07 | Eyepoint Pharmaceuticals Us, Inc. | Porous silicon drug-eluting particles |
| GB0913255D0 (en) | 2009-07-30 | 2009-09-02 | Sisaf Ltd | Topical composition |
| RU2640918C2 (ru) | 2010-11-01 | 2018-01-12 | Псивида Юэс, Инк. | Биоразлагаемые устройства на основе кремния для доставки терапевтических агентов |
| EP2950923B1 (en) | 2013-02-01 | 2022-03-09 | W.R. Grace & CO. - CONN. | Porous silica gel as a carrier for liquid technologies |
| EP2968571A4 (en) | 2013-03-15 | 2016-09-07 | Psivida Inc | BIODEGRADABLE SILICONE BASED COMPOSITIONS FOR THE DELIVERY OF THERAPEUTIC AGENTS |
| US11911499B2 (en) | 2019-11-07 | 2024-02-27 | Resurge Therapeutics, Inc. | System and method for prostate treatment |
| GB202105833D0 (en) * | 2021-04-23 | 2021-06-09 | Nacamed As | Silicon particles for drug delivery |
| US11957654B2 (en) | 2022-01-29 | 2024-04-16 | Resurge Therapeutics, Inc. | Treating benign prostatic hyperplasia |
| US11602516B1 (en) | 2022-01-29 | 2023-03-14 | Resurge Therapeutics Inc. | Treating benign prostatic hyperplasia |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873092A (en) * | 1987-05-21 | 1989-10-10 | Murata Kikai Kabushiki Kaisha | Slow-releasing preparation |
| DE3841397A1 (de) * | 1988-12-08 | 1990-06-21 | Melzer Wolfgang | Poroeser resorbierbarer arzneistofftraeger |
| GB9611437D0 (en) * | 1995-08-03 | 1996-08-07 | Secr Defence | Biomaterial |
| GB9808052D0 (en) * | 1998-04-17 | 1998-06-17 | Secr Defence | Implants for administering substances and methods of producing implants |
| US6537585B1 (en) * | 1999-03-26 | 2003-03-25 | Guilford Pharmaceuticals, Inc. | Methods and compositions for treating solid tumors |
| US6610317B2 (en) * | 1999-05-27 | 2003-08-26 | Acusphere, Inc. | Porous paclitaxel matrices and methods of manufacture thereof |
| GB0008494D0 (en) * | 2000-04-07 | 2000-05-24 | Secr Defence | Microprojectile delivery system |
| AU2001253336A1 (en) * | 2000-04-10 | 2001-10-23 | Teva Pharmaceutical Industries Ltd. | Method 0f administration of paclitaxel-plasma protein formulation |
| GB2365769A (en) * | 2000-08-18 | 2002-02-27 | Secr Defence | Skin preparations containing silicon |
| GB0020610D0 (en) * | 2000-08-21 | 2000-10-11 | Dytech Corp Ltd | Uses of porous carriers |
| GB0104383D0 (en) * | 2001-02-22 | 2001-04-11 | Psimedica Ltd | Cancer Treatment |
| GB0118689D0 (en) * | 2001-08-01 | 2001-09-19 | Psimedica Ltd | Pharmaceutical formulation |
-
2004
- 2004-10-21 WO PCT/GB2004/004442 patent/WO2005041936A2/en not_active Ceased
- 2004-10-21 US US10/576,868 patent/US20070042046A1/en not_active Abandoned
- 2004-10-21 WO PCT/GB2004/004460 patent/WO2005042023A1/en not_active Ceased
- 2004-10-21 ES ES04768977T patent/ES2401435T3/es not_active Expired - Lifetime
- 2004-10-21 DK DK04768977.3T patent/DK1677828T3/da active
- 2004-10-21 EP EP04768977A patent/EP1677828B1/en not_active Expired - Lifetime
- 2004-10-21 JP JP2006536166A patent/JP2007533643A/ja active Pending
- 2004-10-21 SI SI200432005T patent/SI1677828T1/sl unknown
- 2004-10-21 EP EP04768965A patent/EP1694307A2/en not_active Withdrawn
-
2012
- 2012-03-01 JP JP2012045526A patent/JP2012148089A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007533643A5 (enExample) | ||
| JP6325078B2 (ja) | ヘテロ環式化合物およびその使用 | |
| US10899758B2 (en) | Inhibitors of the menin-MLL interaction | |
| ES2838004T3 (es) | Inhibidores de cinasa relacionada con tropomiosina (TRK) | |
| JP2018507097A5 (enExample) | ||
| PE20141042A1 (es) | Nuevos derivados biciclicos de dihidroquinolina-2-ona | |
| RU2015131832A (ru) | Производные 3-алкил-5-фтор-4-замещенного-имино-3,4-дигидропиримидин-2(н)-она в качестве фунгицидов | |
| JP2018537393A5 (enExample) | ||
| NZ589746A (en) | Method for manufacturing medicinal compounds containing dabigatran | |
| JP2015098500A (ja) | アポトーシスシグナル調節キナーゼ阻害剤 | |
| WO2010086863A3 (en) | Crystalline drug-containing coatings | |
| EP3041842A1 (en) | Spirocyclic compounds as tryptophan hydroxylase inhibitors | |
| CL2014001309A1 (es) | Compuestos derivados de [1,2,3] triazolo [4,5-d]-pirimidina, agonistas del receptor de canabinoides 2; proceso de obtencion; composicion farmaceutica; uso para el tratamiento o la profilaxis del dolor, aterosclerosis,retinopatia diabetica, diabetes, fibrosis hepatica, fallo cardiaco, entre otras. | |
| WO2014125505A4 (en) | Silk based porous scaffold and a process for the preparation thereof | |
| EA201500392A1 (ru) | Предшественники и способы переноса при гидротермальном жидкофазном спекании (hlps) | |
| JP2017534662A5 (enExample) | ||
| Yue et al. | An unprecedented ι-type octamolybdate:[TbI 1] 2 [(β-Mo 8 O 26) 0.5 (ι-Mo 8 O 26)] directed by a new tricationic template | |
| Nartowski et al. | Building solids inside nano-space: From confined amorphous through confined solvate to confined ‘metastable’polymorph | |
| CL2013002424A1 (es) | Compuestos derivados de (piridin-4-il)-bencilamidas como moduladores alostericos de nachr alfa-7; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades como alzheimer, ansiedad, esquizofrenia, parkinson, entre otras. | |
| JP2014507270A5 (enExample) | ||
| JP2009511409A5 (enExample) | ||
| JP2013541589A5 (enExample) | ||
| AR081267A1 (es) | Procedimiento de obtencion de la forma cristalina a del febuxostat | |
| WO2011042910A3 (en) | Optical resolution of substituted 2-(2- pyridinylmethylsulphinyl)-1h-benzimidazoles | |
| CN106604916A (zh) | 钾离子竞争性酸阻滞剂的晶型及其制备方法 |